SCHEMBL6080299

SCHEMBL6080299

COC(=O)c1cc(O)c2cc(C)cc(OC)c2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.42
GPR35 Q9HC97 1/20 0.41
POLB P06746 3/20 0.40
RECQL P46063 2/20 0.40
GAA P10253 2/20 0.40
NQO2 P16083 2/20 0.39
LCK P06239 1/20 0.39
KDM4E B2RXH2 3/20 0.38
MAPT P10636 3/20 0.38
SAE1 Q9UBE0 2/20 0.38
UBA2 Q9UBT2 2/20 0.38
NPC1 O15118 1/20 0.38
ABL1 P00519 1/20 0.38
PKM P14618 1/20 0.38
BLM P54132 1/20 0.38
BCL2L1 Q07817 1/20 0.38
MCL1 Q07820 1/20 0.38
RIN1 Q13671 1/20 0.38
GLO1 Q04760 1/20 0.37
PDE4D Q08499 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6593859 0.87 GPR35 (0.56) CNR2GPR35KDM4EMAPTALDH1A1
SCHEMBL6081153 0.84 NQO2 (0.41) CNR2GPR35POLBGAANQO2
SCHEMBL6080304 0.84 LCK (0.38) CNR2GPR35RECQLGAANQO2
SCHEMBL6080169 0.84 MAPT (0.41) GPR35RECQLGAANQO2LCK
SCHEMBL6081104 0.83 NQO2 (0.45) CNR2POLBGAANQO2LCK
SCHEMBL6080867 0.82 ALDH1A1 (0.43) GPR35POLBGAANQO2LCK
SCHEMBL6080683 0.80 NPC1 (0.40) GPR35LCKNPC1MAPK1ALDH1A1
SCHEMBL6080391 0.80 TYR (0.43) POLBGAALCKKDM4EMAPT
SCHEMBL6081303 0.80 DHODH (0.43) KDM4EMAPK1HSD17B10ALDH1A1HPGD
SCHEMBL561666 0.80 PDE10A (0.47) POLBRECQLGAALCKKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL CNR2 734/4885GPR35 1071/4885POLB 2489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.